Scientists uncover new way to make cancers sensitive to treatment

Scientists have uncovered a completely new way to make cancers sensitive to treatment - by targeting antenna-like structures on cells.

Their study found that drug-resistant cancer cells have more and longer antennae than those which are killed by treatment.

Blocking the growth of antennae reactivated a range of cancer treatments that had stopped working, the team at The Institute of Cancer Research, London, found.

The researchers identified changes in cellular antennae known as cilia in different types of cancer cells with resistance to various types of drugs. That suggests that targeting cilia could be a universal way to resensitize cancers to treatment.

The study is published today (Tuesday) in the journal Cell Reports, and was supported by funders including Sarcoma UK, the Wellcome Trust and Cancer Research UK.

Scientists at The Institute of Cancer Research (ICR) - a research institution and charity - studied cells from lung cancer and a soft-tissue cancer called sarcoma in the lab.

The researchers observed that cells that had become resistant to cancer drugs had more, longer cilia - tiny 'antennae' that help cells sense chemical signals.

They then blocked the growth of cilia in drug-resistant cancer cells, and found that their sensitivity to treatment had been restored. Exposure to drugs killed between 35 and 60 per cent of formerly resistant cancer cells - nearly doubling the effectiveness of cancer drugs.

For example, in lung cancer cells without cilia, only 39 per cent of cells survived treatment with a drug called erlotinib, compared with 72 per cent of cells that still had cilia.

Blocking important signaling molecules in cilia also restored cells' response to cancer drugs. Lengthening cilia had the opposite effect, causing cells that previously had responded to treatment to develop resistance.

Cancer cells can evolve in many different ways to become resistant to treatment - for example, changing so that they no longer rely on the molecular weaknesses targeted by the drug.

The researchers believe that the role of cilia in drug resistance is largely linked to important cell signaling molecules they contain.

Next, they aim to study molecular networks in cilia, and the effect of changes in the length and stability of the structures, to better understand their role in cancer drug resistance.

Study leader Dr Barbara Tanos, ICR Fellow in Cancer Therapeutics at The Institute of Cancer Research, London, said:

"We found that small, antenna-like cell structures called cilia play a key role as cancer cells develop resistance to treatment.

"We believe that cilia could help cancer cells become resistant to a wide range of drugs - and therefore that targeting cilia could be a universal way of stripping cancers of their defenses.

"Next, we aim to explore changes to cilia in more depth, to build a more detailed picture of how they are linked to cancer drug resistance and how they might be targeted to restore sensitivity to treatment."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"Combating drug resistance is one of the most important challenges in cancer research today. We urgently need a better understanding of the underlying biology that enables cancer cells to evolve and evade treatment.

"This new study has revealed an intriguing link between drug resistance and cilia - tiny, antenna-like structures that are present on the surface of all cells. The research could open the door to new approaches for attacking cancers, which might block their escape routes from existing treatments."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How AI is advancing mammographic density-based breast cancer risk prediction